Vaccines based on DCs loaded with a pool of peptides derived from melanoma antigens + TBVAs were also observed to exhibit greater anti-tumor efficacy vs. DCs loaded with B16 tumor lysate (containing both melanoma antigens + TBVAs) in association with a superior tumor-infiltrating lymphocyte (TIL) content and CD8+ T cell responses against tumor cells and pericytes/VECs flow-sorted from progressor B16 lesions. The gene discussed is CD8A; the disease is melanoma.